ReviewACS nano2026
MXene Chemistries for Biomedicine: On-Body, In-Body, and Beyond.
Review in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
MXenes, a rapidly expanding family of two-dimensional transition-metal carbides, nitrides, and carbonitrides, have gained considerable attention as highly versatile nanomaterials for biomedical applications owing to their high electrical conductivity, chemically tunable surfaces, mixed ionic-electronic transport, and controllable redox activity. This review provides a structured overview of MXene-based biomedical technologies, organized by their functional interaction with the human body. We first examine on-body applications, highlighting MXene-enabled wearable, epidermal, and implantable bioelectronics. We then discuss in-body applications, including regenerative medicine, advanced cancer therapies, and antimicrobial strategies, emphasizing how MXene chemistry regulates biological interactions and therapeutic performance. Finally, we address applications outside the body, such as biosensing and diagnostic platforms, where MXenes enhance sensitivity, signal transduction, and imaging capabilities. Beyond summarizing recent advances, this review critically analyzes current gaps in knowledge, including long-term biocompatibility, degradation pathways, immune interactions, and structure-activity relationships, which currently limit clinical translation. We conclude by outlining key future directions, including sustainable synthesis, oxidation-resistant and fluorine-free MXenes, and the integration of artificial intelligence to accelerate materials discovery and application-specific design. Together, these insights position MXenes as chemistry-programmable nanoplatforms with strong potential to bridge on-body, in-body, and outside-the-body biomedical technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.